Sign up to save your podcasts
Or
Share Cassava Sciences: The High-Risk Bet You Can’t Afford to Ignore!
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cassava Sciences: The High-Risk Bet You Can’t Afford to Ignore!
In this episode of TechEyeSpy, we dive into the intriguing investment case of Cassava Sciences Inc (NASDAQ: $SAVA). Released in December 2023, this analysis remains highly relevant as we explore the factors driving the potential success of this biotech company. With a focus on its promising Alzheimer's drug development and the surrounding controversies, we evaluate whether this stock is truly "doomed to success." Tune in for an in-depth look at the risks and rewards of investing in Cassava Sciences.
Watch the full episode on YouTube: https://youtu.be/8hJkU5tdPoo
View all episodes
By PRSC WhitleyIn this episode of TechEyeSpy, we dive into the intriguing investment case of Cassava Sciences Inc (NASDAQ: $SAVA). Released in December 2023, this analysis remains highly relevant as we explore the factors driving the potential success of this biotech company. With a focus on its promising Alzheimer's drug development and the surrounding controversies, we evaluate whether this stock is truly "doomed to success." Tune in for an in-depth look at the risks and rewards of investing in Cassava Sciences.
Watch the full episode on YouTube: https://youtu.be/8hJkU5tdPoo